Sophia Wang1,2, Ryan Greene1, Yiqing Song3, Carol Chan4, Heidi Lindroth5, Sikandar Khan6,7,8, Gabriel Rios9, Robert D Sanders10,11, Babar Khan6,7,8. 1. Department of Psychiatry, Indiana University School of Medicine, Indianapolis, IN, USA. 2. Indiana Alzheimer's Disease Research Center, Indiana University School of Medicine, Indianapolis, IN, USA. 3. Fairbanks School of Public Health, Indiana University, Indianapolis, IN, USA. 4. Department of Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine, Baltimore, MD, USA. 5. Division of Nursing Research, Department of Nursing, Mayo Clinic, Rochester, MN, USA. 6. Division of Pulmonary, Critical Care, Sleep and Occupational Medicine, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA. 7. IU Center of Aging Research, Regenstrief Institute, Indianapolis, IN, USA. 8. Center for Health Innovation and Implementation Science, Indiana University School of Medicine, Indianapolis, IN, USA. 9. Ruth Lilly Medical Library, Indiana University School of Medicine, Indianapolis, IN, USA. 10. Specialty of Anaesthetics, University of Sydney, Sydney Medical School/Central Clinical School, Sydney, NSW, Australia. 11. Department of Anaesthetics and Institute of Academic Surgery, Royal Prince Alfred Hospital, Camperdown, NSW, USA.
Abstract
OBJECTIVES: This study seeks to identify Alzheimer's and related dementias (ADRD) biomarkers associated with postoperative delirium (POD) via meta-analysis. DESIGN: A comprehensive search was conducted. Studies met the following inclusion criteria: >18 years of age, identified POD with standardized assessment, and biomarker measured in the AT(N)-X (A = amyloid, T = tau, (N)=neurodegeneration, X-Other) framework. Exclusion criteria: focus on prediction of delirium, delirium superimposed on dementia, other neurologic or psychiatric disorders, or terminal delirium. Reviewers extracted and synthesized data for the meta-analysis. SETTING: Meta-analysis. PARTICIPANTS: Patients with POD. MEASUREMENTS: Primary outcome: association between POD and ATN-X biomarkers. Secondary outcomes involved sample heterogeneity. RESULTS: 28 studies were included in this meta-analysis. Studies focused on inflammatory and neuronal injury biomarkers; there were an insufficient number of studies for amyloid and tau biomarker analysis. Two inflammatory biomarkers (IL-6, and CRP) showed a significant relationship with POD (IL-6 n = 10, standardized mean difference (SMD): 0.53, 95% CI: 0.36-0.70; CRP n = 14, SMD: 0.53, 95% CI: 0.33-0.74). Two neuronal injury biomarkers (blood-based S100B and NfL) were positively associated with POD (S100B n = 5, SMD: 0.40, 95% CI: 0.11-0.69; NFL n = 2, SMD: 0.93, 95% CI: 0.28-1.57). Of note, many analyses were impacted by significant study heterogeneity. CONCLUSIONS: This meta-analysis identified an association between certain inflammatory and neuronal injury biomarkers and POD. Future studies will need to corroborate these relationships and include amyloid and tau biomarkers in order to better understand the relationship between POD and ADRD.
OBJECTIVES: This study seeks to identify Alzheimer's and related dementias (ADRD) biomarkers associated with postoperative delirium (POD) via meta-analysis. DESIGN: A comprehensive search was conducted. Studies met the following inclusion criteria: >18 years of age, identified POD with standardized assessment, and biomarker measured in the AT(N)-X (A = amyloid, T = tau, (N)=neurodegeneration, X-Other) framework. Exclusion criteria: focus on prediction of delirium, delirium superimposed on dementia, other neurologic or psychiatric disorders, or terminal delirium. Reviewers extracted and synthesized data for the meta-analysis. SETTING: Meta-analysis. PARTICIPANTS: Patients with POD. MEASUREMENTS: Primary outcome: association between POD and ATN-X biomarkers. Secondary outcomes involved sample heterogeneity. RESULTS: 28 studies were included in this meta-analysis. Studies focused on inflammatory and neuronal injury biomarkers; there were an insufficient number of studies for amyloid and tau biomarker analysis. Two inflammatory biomarkers (IL-6, and CRP) showed a significant relationship with POD (IL-6 n = 10, standardized mean difference (SMD): 0.53, 95% CI: 0.36-0.70; CRP n = 14, SMD: 0.53, 95% CI: 0.33-0.74). Two neuronal injury biomarkers (blood-based S100B and NfL) were positively associated with POD (S100B n = 5, SMD: 0.40, 95% CI: 0.11-0.69; NFL n = 2, SMD: 0.93, 95% CI: 0.28-1.57). Of note, many analyses were impacted by significant study heterogeneity. CONCLUSIONS: This meta-analysis identified an association between certain inflammatory and neuronal injury biomarkers and POD. Future studies will need to corroborate these relationships and include amyloid and tau biomarkers in order to better understand the relationship between POD and ADRD.
Authors: Sharon K Inouye; Edward R Marcantonio; Cyrus M Kosar; Douglas Tommet; Eva M Schmitt; Thomas G Travison; Jane S Saczynski; Long H Ngo; David C Alsop; Richard N Jones Journal: Alzheimers Dement Date: 2016-04-18 Impact factor: 21.566
Authors: Layth Al Tmimi; Marc Van de Velde; Bart Meyns; Bart Meuris; Paul Sergeant; Koen Milisen; Hans Pottel; Koen Poesen; Steffen Rex Journal: Clin Chem Lab Med Date: 2016-10-01 Impact factor: 3.694
Authors: Cornelia Knaak; Gerald Vorderwülbecke; Claudia Spies; Sophie K Piper; Daniel Hadzidiakos; Friedrich Borchers; Wolf-Rüdiger Brockhaus; Finn M Radtke; Gunnar Lachmann Journal: Acta Anaesthesiol Scand Date: 2019-07-29 Impact factor: 2.105
Authors: Sevdenur Cizginer; Edward Marcantonio; Sarinnapha Vasunilashorn; Alvaro Pascual-Leone; Mouhsin Shafi; Eva M Schmitt; Sharon K Inouye; Richard N Jones Journal: J Geriatr Psychiatry Neurol Date: 2017-11 Impact factor: 2.680
Authors: Emma L Cunningham; Bernadette McGuinness; Daniel F McAuley; Jamie Toombs; Tim Mawhinney; Seamus O'Brien; David Beverland; Jonathan M Schott; Michael P Lunn; Henrik Zetterberg; Anthony P Passmore Journal: Ann Surg Date: 2019-06 Impact factor: 12.969
Authors: P P Pandharipande; T D Girard; J C Jackson; A Morandi; J L Thompson; B T Pun; N E Brummel; C G Hughes; E E Vasilevskis; A K Shintani; K G Moons; S K Geevarghese; A Canonico; R O Hopkins; G R Bernard; R S Dittus; E W Ely Journal: N Engl J Med Date: 2013-10-03 Impact factor: 91.245
Authors: Clifford R Jack; David A Bennett; Kaj Blennow; Maria C Carrillo; Billy Dunn; Samantha Budd Haeberlein; David M Holtzman; William Jagust; Frank Jessen; Jason Karlawish; Enchi Liu; Jose Luis Molinuevo; Thomas Montine; Creighton Phelps; Katherine P Rankin; Christopher C Rowe; Philip Scheltens; Eric Siemers; Heather M Snyder; Reisa Sperling Journal: Alzheimers Dement Date: 2018-04 Impact factor: 21.566
Authors: Ara S Khachaturian; Kathleen M Hayden; John W Devlin; Lee A Fleisher; Sarah Lenz Lock; Colm Cunningham; Esther S Oh; Tamara G Fong; Donna Marie Fick; Edward R Marcantonio; Vijeth Iyengar; Kenneth Rockwood; George A Kuchel; Roderic G Eckenhoff; Alasdair M J MacLullich; Richard N Jones; Daniel Davis; Patricia M D'Antonio; Keith N Fargo; Marilyn S Albert; Jeff D Williamson; Shari M Ling; Joan Weiss; Jason Karlawish; Ronald C Petersen; Dan G Blazer; Zaven S Khachaturian; Sharon K Inouye Journal: Alzheimers Dement Date: 2020-03-24 Impact factor: 16.655